Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO GI 2021 | Immuno-oncology in MSI colorectal cancer

Thierry André • 20 Jan 2021
ASCO GI 2021
Colorectal Cancer Gastrointestinal Cancer

Thierry André, MD, Hospital Saint Antoine, Paris, France, outlines advances in the use of immunotherapy in patients with microsatellite instable (MSI) colorectal cancer, and future approaches in this field. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Thierry André

2:11
Pembrolizumab vs. chemo in first-line mCRC
Thierry André • 18 Jan 2021
3:53
GARNET: dostarlimab, a PD-1 antibody in advanced solid tumors
Thierry André • 18 Jan 2021
2:31
IDEA-FRANCE: ctDNA as a predictive value for adjuvant treatment duration
Thierry André • 29 Sep 2019
2:20
AVANT: bevacizumab + oxaliplatin-based chemo for colon cancer
Thierry André • 29 Sep 2019

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:16
Entinostat with nivolumab in pancreatic ductal adenocarcinoma
Marina Baretti • 9 Apr 2024
2:11
COMPASSION-15: cadonilimab in advanced gastric cancers
Yelena Janjigian • 8 Apr 2024
1:28
Evolving biomarker driven therapies to overcome gastric cancer tumor resistance
Yelena Janjigian • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals